Advertisement

STXS

Stereotaxis, Inc.

Healthcare · USD

Set alert

Price alert · STXS

All alert types
0.86 USD -0.05 -5.21%
As of Oct 30, 2026 Extended hours 0.90 +4.10%
Bid
0.86 × 100
Ask
0.87 × 600
0.8129 Day range 0.9183
0.8626 52-week range 2.92
YTD
-62.50%
1 year
-70.46%
Open
0.90
Prev close
0.91
Mkt cap
86.43M
Vol
1.44M
Avg vol
580.54K
EPS
-0.24
P/E
0.00
Div yield
0.00%
More statistics
Low
0.8129
High
0.9183
Forward P/E
-13.06
Beta
1.55
Short ratio
6.26
Inst. own
48.48%
Dividend
0.00
Ex-div date
50-d avg
2.08
200-d avg
2.14
1y target
4.50

5D chart

Chart tools
Interval
STXS five-day price chart0.950.970.991.021.04Oct 23Oct 26Oct 27Oct 28Oct 29

Key statistics

Market cap
199.11M
Enterprise value
199.95M
Trailing P/E
0.00
Forward P/E
-13.06
PEG ratio
0.00
Price / sales
7.92
Price / book
18.36
EPS (TTM)
-0.27
Beta
1.55
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-85.79%
Revenue (TTM)
25.14M
Revenue growth
17.90%
Free cash flow
0
Total cash
10.66M
Total debt
6.13M
Return on equity
-106.46%
Shares outstanding
84.73M
Short % of float
3.65%
50-day average
2.08
200-day average
2.14

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 4.50 +421.7% upside
Target (low)
4.00
Target (mean)
4.50
Target (high)
5.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
  • Strong buy2
  • Buy2
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate -0.065.

Earnings history

Financials — quick view

All financials
STXS Revenue — quarterly 7.67M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
STXS Net income — quarterly -4.47M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
STXS EPS — quarterly -0.05
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

STXS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 11, 2024Sep 1, 2024-0.05-0.08-0.03-60.00%
Aug 12, 2024Jun 1, 2024-0.04-0.07-0.03-75.00%
May 13, 2024Mar 1, 2024-0.07-0.06+0.01+14.29%
Mar 4, 2024Dec 1, 2023-0.07-0.070.000.00%
Nov 9, 2023Sep 1, 2023-0.05-0.07-0.02-40.00%
Aug 10, 2023Jun 1, 2023-0.06-0.07-0.01-16.67%

Upgrades / downgrades

STXS analyst upgrades and downgrades
DateFirmActionFromTo
Mar 5, 2024Lake StreetmainBuyBuy
Mar 5, 2024Roth MKMreitBuyBuy
Jan 10, 2024Roth MKMinit—Buy
Mar 6, 2023Piper Sandlermain—Overweight
Mar 6, 2023Lake Streetmain—Buy
Mar 6, 2023B. Riley Securitiesmain—Buy

About Stereotaxis, Inc.

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States

News

Your note

Sign in to keep a note on STXS — it syncs with the Stock Master app.

Insider holders

STXS insider holders
InsiderRelationLatest transactionDateShares held
BENFER DAVID WDirectorStock Award(Grant)Jun 30, 2024581,714
CURET MYRIAM JDirectorStock Award(Grant)Jun 30, 2024244,945
FISCHEL NATHANDirector and Beneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)Jun 30, 202414,211,100
ISAAC PAUL JDirectorPurchaseAug 19, 20240
LEVIN ROSS B.DirectorStock Award(Grant)Jun 30, 2024431,032
MENAWAT ARUN SWARUP PH.D.DirectorStock Award(Grant)Jun 30, 2024845,344

Institution ownership

STXS institution ownership
Holder% heldSharesValueReported
DAFNA Capital Management, LLC20.73%13,680,55432.15MSep 29, 2024
Lagoda Investment Management, L.P.5.80%3,830,4359.00MSep 29, 2024
Blackrock Inc.5.80%3,825,5808.99MSep 29, 2024
Vanguard Group Inc4.69%3,093,3647.27MSep 29, 2024
Arbiter Partners Capital Management LLC4.23%2,791,0686.56MSep 29, 2024
Redmile Group, LLC3.19%2,108,2194.95MSep 29, 2024

Fund ownership

STXS fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.50%1,652,3613.88MSep 29, 2024
iShares Russell 2000 ETF1.98%1,310,1443.08MOct 30, 2024
Vanguard Extended Market Index Fund1.43%943,6522.22MSep 29, 2024
Mutual Fund Ser Tr-AlphaCentric Robotics & Automation Fund0.91%600,0001.41MSep 29, 2024
Fidelity Small Cap Index Fund0.85%560,2631.32MAug 30, 2024
iShares Russell 2000 Growth ETF0.67%444,2201.04MOct 30, 2024
Advertisement